001389097 000__ 02224cam\\2200529\i\4500
001389097 001__ 1389097
001389097 003__ OCoLC
001389097 005__ 20220303003055.0
001389097 007__ he\bmb024bbca
001389097 008__ 180705s2017\\\\dcu\\\\\bb\\\f000\0\eng\c
001389097 035__ $$a(OCoLC)1042815421
001389097 040__ $$aGPO$$beng$$erda$$cGPO$$dOCLCF$$dOCLCA$$dNJR$$dOCLCA$$dISE
001389097 042__ $$apcc
001389097 043__ $$an-us---
001389097 049__ $$aISEA
001389097 074__ $$a1016-B (MF)
001389097 0860_ $$aY 4.G 74/7:115-33
001389097 088__ $$aSerial no. 115-33 (United States. Congress. House. Committee on Oversight and Government Reform)
001389097 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Oversight and Government Reform.$$bSubcommittee on Health Care, Benefits, and Administrative Rules,$$eauthor.
001389097 24510 $$aExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain :$$bhearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017.
001389097 264_1 $$aWashington :$$bU.S. Government Publishing Office,$$c2017.
001389097 300__ $$aiii, 54 pages ;$$c24 cm
001389097 336__ $$atext$$btxt$$2rdacontent
001389097 337__ $$amicroform$$bh$$2rdamedia
001389097 338__ $$amicrofiche$$bhe$$2rdacarrier
001389097 500__ $$a"Serial no. 115-33."
001389097 500__ $$aShipping list no.: 2018-0099-M.
001389097 504__ $$aIncludes bibliographical references.
001389097 533__ $$aMicrofiche.$$b[Washington, D.C.] :$$cU.S. Government Printing Office,$$d[2018]$$e1 microfiche : negative.
001389097 650_0 $$aPharmaceutical industry$$xCorrupt practices$$zUnited States.
001389097 650_0 $$aPharmaceutical policy$$zUnited States.
001389097 650_0 $$aGeneric drugs$$xDevelopment$$zUnited States.
001389097 650_0 $$aPrescription pricing$$zUnited States.
001389097 650_0 $$aCompetition$$zUnited States.
001389097 650_0 $$aConsumer protection$$zUnited States.
001389097 650_7 $$aCompetition.$$2fast$$0(OCoLC)fst00871464
001389097 650_7 $$aConsumer protection.$$2fast$$0(OCoLC)fst00876358
001389097 650_7 $$aPharmaceutical industry$$xCorrupt practices.$$2fast$$0(OCoLC)fst01060133
001389097 650_7 $$aPharmaceutical policy.$$2fast$$0(OCoLC)fst01060194
001389097 650_7 $$aPrescription pricing.$$2fast$$0(OCoLC)fst01075656
001389097 651_7 $$aUnited States.$$2fast$$0(OCoLC)fst01204155
001389097 655_7 $$aLegislative hearings.$$2fast$$0(OCoLC)fst01910825
001389097 655_7 $$aLegislative hearings.$$2lcgft
001389097 852__ $$bdfich
001389097 852__ $$bedoc$$hY 4.G 74/7:115-33
001389097 85640 $$uhttp://purl.fdlp.gov/GPO/gpo86757
001389097 909CO $$ooai:library.usi.edu:1389097$$pGLOBAL_SET
001389097 980__ $$aBIB
001389097 980__ $$aEGOV
001389097 982__ $$aGovernment E-Resource
001389097 983__ $$aOnline
001389097 994__ $$aC0$$bISE